A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Start Date
8/18/2025
Completion Date
7/1/2028
Summary
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
NBI-1065845
Placebo
Conditions
Locations
Neurocrine Clinical Site
Oceanside, California 92056
United States
Neurocrine Clinical Site
Orange, California 92868
United States
Neurocrine Clinical Site
San Jose, California 95124
United States
Neurocrine Clinical Site
New Haven, Connecticut 06520
United States
Neurocrine Clinical Site
Miami Gardens, Florida 33014
United States
Neurocrine Clinical Site
Orlando, Florida 32803
United States
Neurocrine Clinical Site
Palm Bay, Florida 32905
United States
Neurocrine Clinical Site
Tampa, Florida 33629
United States
Neurocrine Clinical Site
Iowa City, Iowa 52242
United States
Neurocrine Clinical Site
Marrero, Louisiana 70072
United States
Neurocrine Clinical Site
O'Fallon, Missouri 63368
United States
Neurocrine Clinical Site
Albuquerque, New Mexico 87109
United States
Neurocrine Clinical Site
Glen Oaks, New York 11004
United States
Neurocrine Clinical Site
Charlotte, North Carolina 28211
United States
Neurocrine Clinical Site
Edmond, Oklahoma 73013
United States
Neurocrine Clinical Site
Oklahoma City, Oklahoma 73112
United States
Neurocrine Clinical Site
Philadelphia, Pennsylvania 19104
United States
Neurocrine Clinical Site
Austin, Texas 78712
United States
Neurocrine Clinical Site
Bellaire, Texas 77401
United States
Neurocrine Clinical Site
Friendswood, Texas 77546
United States
Neurocrine Clinical Site
Stafford, Texas 77477
United States
Neurocrine Clinical Site
Wichita Falls, Texas 76309
United States
Neurocrine Clinical Site
Draper, Utah 84020
United States
Neurocrine Clinical Site
Roanoke, Virginia 24018
United States
Neurocrine Clinical Site
Carlton, Victoria 3053
Australia
Neurocrine Clinical Site
Melbourne, Victoria 3004
Australia
Neurocrine Clinical Site
Parkville, Victoria 3050
Australia
Neurocrine Clinical Site
Sofia, 1303
Bulgaria
Neurocrine Clinical Site
Sofia, 1408
Bulgaria
Neurocrine Clinical Site
Sofia, 1510
Bulgaria
Neurocrine Clinical Site
Sofia, 1680
Bulgaria
Neurocrine Clinical Site
Calgary, Alberta T2N 2T9
Canada
Neurocrine Clinical Site
North Vancouver, British Columbia V7P 2T4
Canada
Neurocrine Clinical Site
Kingston, Ontario K7L 4X3
Canada
Neurocrine Clinical Site
Sherbrooke, Quebec J1L 0H8
Canada
Neurocrine Clinical Site
Toronto, M5H 1A1
Canada
Neurocrine Clinical Site
Tallinn, 10138
Estonia
Neurocrine Clinical Site
Tallinn, 11315
Estonia
Neurocrine Clinical Site
Tartu, 50417
Estonia
Neurocrine Clinical Site
Milan, 20127
Italy
Neurocrine Clinical Site
Roma, 168
Italy
Neurocrine Clinical Site
Rome, 168
Italy
Neurocrine Clinical Site
Torino, 10126
Italy
Neurocrine Clinical Site
Bialystok, 15-879
Poland
Neurocrine Clinical Site
Bydgoszcz, 85-794
Poland
Neurocrine Clinical Site
Gdansk, 80-283
Poland
Neurocrine Clinical Site
Belgrade, 11000
Serbia
Neurocrine Clinical Site
Kovin, 26220
Serbia
Neurocrine Clinical Site
Kragujevac, 34000
Serbia
Neurocrine Clinical Site
Ansan-si, Gyeonggi-do 15355
South Korea
Neurocrine Clinical Site
Seoul, 02841
South Korea
Neurocrine Clinical Site
Seoul, 06351
South Korea
Neurocrine Clinical Site
Seoul, 3181
South Korea
Neurocrine Clinical Site
Alcorcón, Madrid 28922
Spain
Neurocrine Clinical Site
Barcelona, 08025
Spain
Neurocrine Clinical Site
Barcelona, 08035
Spain
Neurocrine Clinical Site
Keelung, 204
Taiwan
Neurocrine Clinical Site
Taipei, 10449
Taiwan
Neurocrine Clinical Site
Taipei, 110
Taiwan
Neurocrine Clinical Site
Taipei, 11217
Taiwan